All In Biotech

NDA 211759 · Carwin Pharm Assoc

Vyscoxa

Celecoxib · Oral · Nonsteroidal Anti-inflammatory Drug

Last checked: Nov 19, 2026Latest source record: Jul 29, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Jul 29, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

631

125 Phase 3, 38 recruiting

FAERS reports

35,685

26,846 serious, 6,053 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use. ( 5.1 ) • VYSCOXA is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. ( 4 , 5.1 ) • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer...

What it is approved for

From the label in effect Jul 31, 2025.

1. INDICATIONS AND USAGE VYSCOXA is indicated In adults for the management of the signs and symptoms of: VYSCOXA contains celecoxib, a nonsteroidal anti-inflammatory drug, and is indicated: In adults for • Osteoarthritis (OA) ( 1.1 ) • Rheumatoid Arthritis (RA) ( 1.2 ) • Ankylosing Spondylitis (AS) ( 1.3 ) In pediatric patients two years and older for • Juvenile Rheumatoid Arthritis (JRA) ( 1.4 ) Limitations of Use VYSCOXA must be administered on an empty stomach at least 2 hours before or 1 hour after food. Taking VYSCOXA with food results in plasma exposures of celecoxib up to 50% higher than intended. If patients cannot tolerate VYSCOXA in the fasted state, discontinue use of VYSCOXA ( 2.1 , 5 , 12 ) 1.1 Osteoarthritis (OA) [ see Clinical Studies (14.1) ]. 1.2 Rheumatoid Arthritis (RA) [ see Clinical Studies (14.2) ]. 1.3 Ankylosing Spondylitis (AS) [ see Clinical Studies (14.3) ]. In pediatric patients two years of age and older for the management of the signs and symptoms of: 1.4 Juvenile Rheumatoid Arthritis (JRA) [ see Clinical Studies (14.4) ]. Limitations of Use VYSCOXA must be administered on an empty stomach at least 2 hours before or 1 hour after food. Taking VYSCOXA with food results in plasma exposures of celecoxib up to 50% higher than intended. If patients cannot tolerate VYSCOXA in the fasted state, discontinue use of VYSCOXA (reference Sections 2.1 , 5 , 12 ). VYSCOXA is NOT indicated for the management of acute pain or treatment of primary dysmenorrhea.

Mechanism: Celecoxib has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of COX-2. Celecoxib is a potent inhibitor of prostaglandin synthesis in vitro . Celecoxib concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Since celecoxib is an inhibitor of prostaglandin synthesis, its mode of action...

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VYSCOXA · CELECOXIB 10MG/ML · SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Celecoxib" as an intervention, any sponsor and status, largest first.

All 631 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective5,458
  • off label use3,498
  • fatigue3,409
  • arthralgia3,339
  • pain3,325
  • nausea3,299
  • diarrhoea2,965
  • vomiting2,687
  • rheumatoid arthritis2,594
  • rash2,565
  • headache2,487
  • condition aggravated2,434

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004857
2005679
2006215
2007349
2008556
2009465
2010444
2011658
2012544
2013465
2014450
20151,302
20161,642
20171,740
20181,918
20192,365
20202,679
20212,689
20223,027
20232,739
20243,358
20254,089
20262,455

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,234 on PubMed

Sponsor: Carwin Pharm Assoc

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.